We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.06B
AUM Growth
+$329M
Cap. Flow
-$217M
Cap. Flow %
-5.35%
Top 10 Hldgs %
37.39%
Holding
124
New
4
Increased
35
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$16.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.8M
4
BPMC
Blueprint Medicines
BPMC
+$12.7M
5
IMVT icon
Immunovant
IMVT
+$12.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$84.9M
2
HUM icon
Humana
HUM
+$62.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.6M
4
ABCM
Abcam PLC
ABCM
+$28.9M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
2 Consumer Staples 1.41%
3 Industrials 1.03%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
Edwards Lifesciences
EW
$53.4B
$49.4M 1.22%
647,300
– –
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$49.1M 1.21%
835,776
-295,431
-26% -$16.6M
WST icon
28
West Pharmaceutical
WST
$25B
$48.3M 1.19%
137,250
-64,750
-32% -$22.9M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$1.94B
$47.9M 1.18%
2,152,173
-557,888
-21% -$12.5M
MDGL icon
30
Madrigal Pharmaceuticals
MDGL
$11.8B
$45.9M 1.13%
198,169
+1,800
+0.9% +$315K
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$28.9B
$45M 1.11%
235,000
-44,500
-16% -$7.58M
OLK
32
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$42.2M 1.04%
1,676,500
– –
ACCD
33
DELISTED
Accolade Inc
ACCD
$41.9M 1.03%
3,485,000
+572,000
+20% +$4.9M
IMVT icon
34
Immunovant
IMVT
$8.18B
$41.4M 1.02%
983,301
+338,957
+53% +$12.5M
LLY icon
35
Eli Lilly
LLY
$1.09T
$40.5M 1%
+69,500
New +$40.6M
KYMR icon
36
Kymera Therapeutics
KYMR
$9B
$38.8M 0.95%
1,522,238
+17,887
+1% +$320K
CLDX icon
37
Celldex Therapeutics
CLDX
$3.34B
$38.5M 0.95%
969,646
+469,545
+94% +$13.8M
IRTC icon
38
iRhythm Holdings
IRTC
$4.09B
$37.5M 0.92%
350,750
– –
ASND icon
39
Ascendis Pharma A/S
ASND
$16.5B
$36.5M 0.9%
290,000
-135,500
-32% -$13.5M
PCRX icon
40
Pacira BioSciences
PCRX
$976M
$35.6M 0.88%
1,055,500
– –
LFST icon
41
Lifestance Health
LFST
$4.6B
$35.5M 0.87%
4,535,000
+865,000
+24% +$5.58M
AZTA icon
42
Azenta
AZTA
$1.54B
$33.1M 0.81%
507,500
+30,000
+6% +$1.63M
SRPT icon
43
Sarepta Therapeutics
SRPT
$1.79B
$31.6M 0.78%
327,600
-64,400
-16% -$6.18M
ZLAB icon
44
Zai Lab
ZLAB
$2.61B
$31.1M 0.77%
1,137,023
-100,000
-8% -$2.64M
LEGN icon
45
Legend Biotech
LEGN
$3.99B
$29.6M 0.73%
492,444
+34,179
+7% +$2.17M
WRBY icon
46
Warby Parker
WRBY
$3.24B
$28.6M 0.7%
2,028,300
+453,300
+29% +$5.65M
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$25.2M 0.62%
1,081,064
-338,086
-24% -$6.67M
TVTX icon
48
Travere Therapeutics
TVTX
$5.76B
$24.9M 0.61%
2,771,446
+963,704
+53% +$7.02M
MRUS
49
DELISTED
Merus
MRUS
$24M 0.59%
872,069
+33,641
+4% +$786K
DVAX
50
DELISTED
Dynavax Technologies
DVAX
$23.4M 0.58%
1,675,474
-138,284
-8% -$1.92M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rock Springs Capital Management held 124 positions worth $4.06B, up 8.8% from $3.73B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $217M in Q4 2023, closing 20 positions and reducing 29 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Eli Lilly worth $40.5M.

  • Rock Springs Capital Management's largest Q4 2023 buy was Eli Lilly: 69,500 shares worth $40.5M.
  • Rock Springs Capital Management added most to Celldex Therapeutics in Q4 2023, an estimated $13.8M increase.
  • Rock Springs Capital Management's biggest Q4 2023 reduction was Humana, cutting an estimated $62.4M.
  • Rock Springs Capital Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $84.9M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $4.06B portfolio in Q4 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 20 in Q4 2023.
  • Rock Springs Capital Management's portfolio value rose 8.8% quarter-over-quarter to $4.06B.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.